Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.

Sastre, Javier; Serrano, Juan Jose; Fernández, Cristina; Ramirez, Carmen; Ortega, Luis; García-Paredes, Beatriz; Corona, Juan; Alfonso, Rosario; Córdoba, Sofía; Díaz-Rubio, Eduardo

Sastre, Javier; Serrano, Juan Jose; Fernández, Cristina; Ramirez, Carmen; Ortega, Luis; García-Paredes, Beatriz; Corona, Juan; Alfonso, Rosario; Córdoba, Sofía; Díaz-Rubio, Eduardo.

Afiliação

Sastre J; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Center affiliated to Red Temática de Investigación Cooperativa (RD06/0020/0021) Instituto Carlos III, Spanish Ministry of Science and Innovation, Spain. Electronic address: jsastrev@salud.madrid.org.
Serrano JJ; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Center affiliated to Red Temática de Investigación Cooperativa (RD06/0020/0021) Instituto Carlos III, Spanish Ministry of Science and Innovation, Spain.
Fernández C; Biostatistic and Preventive Medicine Department, Hospital Clínico San Carlos, Madrid, Spain.
Ramirez C; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Center affiliated to Red Temática de Investigación Cooperativa (RD06/0020/0021) Instituto Carlos III, Spanish Ministry of Science and Innovation, Spain.
Ortega L; Pathology Department, Hospital Clínico San Carlos, Madrid, Spain.
García-Paredes B; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Center affiliated to Red Temática de Investigación Cooperativa (RD06/0020/0021) Instituto Carlos III, Spanish Ministry of Science and Innovation, Spain.
Corona J; Radiation Oncology Department, Hospital Clínico San Carlos, Madrid, Spain.
Alfonso R; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Center affiliated to Red Temática de Investigación Cooperativa (RD06/0020/0021) Instituto Carlos III, Spanish Ministry of Science and Innovation, Spain.
Córdoba S; Radiation Oncology Department, Hospital Clínico San Carlos, Madrid, Spain.
Díaz-Rubio E; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Center affiliated to Red Temática de Investigación Cooperativa (RD06/0020/0021) Instituto Carlos III, Spanish Ministry of Science and Innovation, Spain.

Clin Colorectal Cancer ; 15(2): 128-34, 2016 06.

Article em En | MEDLINE | ID: mdl-26385572

Assuntos

Adenocarcinoma/terapia; Quimiorradioterapia Adjuvante/métodos; Quimioterapia Adjuvante/métodos; Terapia Neoadjuvante/métodos; Neoplasias Retais/terapia; Adenocarcinoma/mortalidade; Adulto; Idoso; Idoso de 80 Anos ou mais; Procedimentos Cirúrgicos do Sistema Digestório; Intervalo Livre de Doença; Feminino; Fluoruracila/administração & dosagem; Humanos; Estimativa de Kaplan-Meier; Masculino; Pessoa de Meia-Idade; Modelos de Riscos Proporcionais; Neoplasias Retais/mortalidade; Fatores de Risco; Resultado do Tratamento

Palavras-chave

Capecitabine; FOLFOX/XELOX; Neoadjuvant chemoradiation; Rectal cancer; Risk-adapted adjuvant treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Adenocarcinoma / Quimioterapia Adjuvante / Terapia Neoadjuvante / Quimiorradioterapia Adjuvante Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google